A new study led by scientists at VCU Massey Cancer Center has shown that an experimental drug known as AZ32 selectively sensitizes brain tumors to radiation and significantly extends the survival of mouse models with human ...
Jun 27, 2018
0
253
Researchers have discovered a new class of drug that has the potential to help cancer patients who no longer respond to existing therapies.
Apr 10, 2018
0
142
A short-term pause in HIV treatment during a carefully monitored clinical trial does not lead to lasting expansion of the HIV reservoir nor cause irreversible damage to the immune system, new findings suggest.
Jan 11, 2018
0
5
Not every drug designed by pharmaceutical companies makes it to the market; very few do. Only 9.6% of new drugs in development in the years 2006-2015 successfully made it to the market to be used by patients. That's because ...
Oct 11, 2017
0
4
Concurrent administration of the T-cell stimulating anti-OX40 antibody and the immune checkpoint inhibitor anti-PD1 antibody attenuated the effect of anti-OX40 and resulted in poor treatment outcomes in mice.
Aug 28, 2017
0
0
A new study by researchers at The Ohio State University Comprehensive Cancer Center - Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC - James) has identified a mechanism by which cancer cells ...
Mar 2, 2017
0
19
The long-term safety of gene transfer to treat neovascular age-related macular degeneration (NVAMD), and the production of two therapeutic proteins encoded by those genes for at least 2.5 years in the eyes of patients with ...
Oct 20, 2016
0
1
(HealthDay)—While cooling patients whose hearts stop suddenly outside the hospital may help improve outcomes, it doesn't seem to show the same benefit when cardiac arrest happens in a hospital setting, a new study suggests.
Oct 4, 2016
0
0
Scientists have developed a new method of measuring the activity of disease-causing mutations in the LRRK2 gene, a major cause of inherited Parkinson's disease.
Jul 29, 2016
0
1
The new Concise Guide to PHARMACOLOGY 2015/2016 provides a valuable and unique overview of the key properties of more than 1,700 human drug targets, focusing on those exploited currently in the clinic or with future therapeutic ...
Jan 4, 2016
0
0
